Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.

Breast cancer drug blocked for NHS use as price talks break down for third time - Nice said it was ‘extremely disappointed’ ...

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers ...

The National Institute for Health and Care Excellence (Nice) said it is "extremely disappointed" it will be unable to ...

Talks with AZ and Daiichi to negotiate a fair price for Enhertu for treatment of advanced HER2-low breast cancer in the U.K.

Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.

In the talks both ourselves and NHS England continued to offer as much flexibility as possible, but despite the intervention of Secretary of State for Health Wes Streeting, the companies did not put ...

It comes after Health Secretary Wes Streeting met with the charity Breast Cancer Now to discuss the issue around Enhertu. In a post on X, formerly Twitter, from October 24 he wrote: "An improved offer ...

A woman whose cancer has spread to her bones, back, pelvis and neck but has been denied a life-extending drug because she ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...

ENHERTU (5.4 mg/kg) is approved in more than 65 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have ...